CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)
MWN-AI** Summary
PreveCeutical Medical Inc. ("PreveCeutical") has announced a significant corporate action regarding its upcoming reclassification and plan of arrangement with BioGene Therapeutics Inc. ("BioGene"), scheduled to be effective on November 25, 2025. This arrangement involves the distribution of 12 million common shares of BioGene (referred to as "BioGene Spinout Shares") to PreveCeutical's shareholders.
As part of this statutory plan of arrangement, PreveCeutical will undergo a name and structural change: its current shares will be renamed 'Class A Common Shares without par value.' Additionally, a new class of shares called "New PreveCeutical Shares" will be created, which will have similar terms and rights to the existing shares just prior to the arrangement's closure.
On the effective date, each PreveCeutical Current Share held by shareholders will be exchanged for one New PreveCeutical Share and an additional 0.02 BioGene Spinout Shares, rounded down to the nearest whole share. This mechanism is designed to optimize shareholder value and streamline the company's capital structure in conjunction with BioGene's shares.
Key transitional details include a delisting of the current shares on November 24, 2025, and the commencement of trading for the new shares on November 25, 2025, under a new CUSIP and ISIN number.
PreveCeutical has urged shareholders to review the full details of the arrangement in its related news releases. For inquiries, stakeholders are encouraged to contact the CSE Listings department directly. This arrangement reflects PreveCeutical's effort to align with strategic partners like BioGene and enhance shareholder engagement moving forward.
MWN-AI** Analysis
PreveCeutical Medical Inc. (CSE: PREV) is undergoing a significant transformation with its announced plan of arrangement involving BioGene Therapeutics Inc., set to take effect on November 25, 2025. As a financial analyst, it’s crucial for current and prospective shareholders to understand the implications of this corporate action.
Firstly, the reclassification will see PreveCeutical's common shares renamed as ‘Class A Common Shares’ while introducing a new category of shares, termed ‘New PreveCeutical Shares’. Each existing share will convert into one New PreveCeutical Share and entitle shareholders to 0.02 BioGene shares. This distribution offers shareholders immediate value through the spinout shares, yet it also dilutes the total equity of PreveCeutical, which may impact shareholder sentiments negatively post-arrangement.
Investors should consider the long-term viability of both PreveCeutical and BioGene upon completion of this arrangement. The establishment of BioGene as a separate entity could attract interest for its specific research and development focus, potentially enhancing shareholder value if managed correctly. However, the success of this venture largely depends on the market's perception and the future performance of BioGene, which remains uncertain.
Given the dilution effect, short-term volatility may be expected around the effective trading date. Investors should evaluate their risk tolerance and investment horizon. Those seeking immediate gains may choose to hold off on purchasing shares until after the spinout, while long-term investors might seize the opportunity to buy into PreveCeutical’s evolving structure.
In conclusion, while the arrangement with BioGene presents potential opportunities for growth and diversification, investors must remain vigilant and evaluate the evolving landscape keenly. Careful monitoring of both entities, their performance metrics, and market conditions will be essential moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Toronto, Ontario--(Newsfile Corp. - Le 24 novembre/November 2025) - PreveCeutical Medical Inc. ("PreveCeutical") has announced the effective date of the reclassification as well as the previously announced plan of arrangement with BioGene Therapeutics Inc. ("BioGene") to occur on November 25, 2025.
Pursuant to the Arrangement Agreement (the "Arrangement Agreement") 12,000,000 common shares of BioGene Therapeutics Inc. (the “BioGene Spinout Shares”) will be distributed to the shareholders of PreveCeutical (the “Shareholders”). The Arrangement will be undertaken by way of a statutory plan of arrangement whereby the Issuer will: (i) rename and re-designate its common shares (the “PreveCeutical Current Shares”) as ‘Class A Common Shares without par value’; and (ii) amend the authorized share structure of the Issuer to create a new class of shares (the “New PreveCeutical Shares”) consisting of an unlimited number of ‘common shares without par value’ with terms and special rights and restrictions identical to those of the PreveCeutical Current Shares immediately prior to the closing of the Arrangement.
Upon the effective date, each PreveCeutical Current Share held by PreveCeutical shareholders on the effective date of the Arrangement will be exchanged for one New PreveCeutical Share and 0.02 BioGene Spinout Shares rounded down to the nearest whole share.
For more information, please see the news releases issued by PreveCeutical.
_________________________________
PreveCeutical Medical Inc. (« PreveCeutical ») a annoncé que la date d’entrée en vigueur de la reclassification ainsi que du plan d’arrangement précédemment annoncé avec BioGene Therapeutics Inc. (« BioGene ») sera le 25 novembre 2025.
Conformément à la convention d’arrangement (la « Convention d’arrangement »), 12 000 000 d’actions ordinaires de BioGene Therapeutics Inc. (les « Actions issues de la scission de BioGene ») seront distribuées aux actionnaires de PreveCeutical (les « Actionnaires »). L’arrangement sera réalisé au moyen d’un plan d’arrangement légal en vertu duquel l’Émetteur : i) renommera et désignera ses actions ordinaires (les « Actions actuelles de PreveCeutical ») comme des « Actions ordinaires de catégorie A sans valeur nominale » ; et ii) modifiera la structure des actions autorisées de l’Émetteur afin de créer une nouvelle catégorie d’actions (les « Nouvelles Actions de PreveCeutical ») composée d’un nombre illimité d’« actions ordinaires sans valeur nominale » assorties de modalités, de droits spéciaux et de restrictions identiques à ceux des Actions actuelles de PreveCeutical immédiatement avant la clôture de l’arrangement.
À la date d’entrée en vigueur, chaque Action actuelle PreveCeutical détenue par les actionnaires de PreveCeutical à cette date sera échangée contre une Nouvelle Action PreveCeutical et 0,02 Action BioGene issue de la scission, arrondie à l’unité inférieure.
Pour plus d’information, veuillez consulter les communiqués de presse publiés par PreveCeutical.
| OLD Security Name/ANCIEN Nom de sécurité: | PreveCeutical Medical Inc. - Common Shares |
| Symbol(s)/Symbole(s): | PREV |
| CUSIP & ISIN: | 74141E104/CA74141E1043 |
| Anticipated Payment Date/Date de Paiement Prévue : | Le 25 NOV 2025 |
| Delist Date/Date de radiation : | Le 24 NOV 2025 |
| NEW Security Name/NOUVEAU Nom de sécurité : | PreveCeutical Medical Inc. - Common Shares |
| Symbol(s)/Symbole(s) : | PREV |
| NEW/Nouveau CUSIP : | 74143C 10 6 |
| NEW/Nouveau ISIN : | CA 74143C 10 6 8 |
| Effective Trading Date/Date de négociation effective : | Le 25 NOV 2025 |
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com
Pour toute question, pour obtenir de l’information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l’adresse: Listings@thecse.com
FAQ**
How does the reclassification of PreveCeutical Medical Inc. PREV:CC and the arrangement with BioGene Therapeutics Inc. impact investor sentiment in the Toronto market for biotech stocks?
What potential risks and benefits do shareholders of PreveCeutical Medical Inc. PREV:CC face as they transition to holding New PreveCeutical Shares and BioGene Spinout Shares?
In light of the arrangement with BioGene Therapeutics Inc., how might the restructured share structure of PreveCeutical Medical Inc. PREV:CC affect its capitalization and overall market position?
What trends in the Toronto biotech sector could influence the future performance of PreveCeutical Medical Inc. PREV:CC following the completion of its share reclassification and arrangement?
**MWN-AI FAQ is based on asking OpenAI questions about PreveCeutical Medical Inc (OTC: PRVCF).
NASDAQ: PRVCF
PRVCF Trading
-21.43% G/L:
$0.0143 Last:
10,000 Volume:
$0.0143 Open:
